

Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

NCT06985706

Status	RECRUITING
Phase	Phase 3
Sponsor	Belfast Health and Social Care Trust
Enrollment	264 participants

Key Eligibility Criteria

Inclusion (4)

- Adults (>18 years)
- Diabetes type 1 or type 2
- Presented with severe centre-involving (CI)-DMO (CRT e400µm)
- Within the first year of initiating anti-VEGF therapy but who still have DMO and their CRT is below 400 µm (and it remains, at the time of randomisation) following anti-VEGF therapy in either one eye or both eyes

Exclusion (10)

- Causes of macular oedema other than DMO
- DMO with CRT e400µm
- Receipt of anti-VEGFs before their presentation with severe DMO (previous macular laser treatment for DMO is allowed)
- Use of unlicensed anti-VEGFs (e.g. bevacizumab)
- Inability, for any reason, to attend study visits
- ... and 5 more (see full listing online)

Locations (22 total)

The Royal Hospitals Belfast, Belfast, United Kingdom
Birmingham and Midland Eye Centre, Birmingham, United Kingdom
Sussex Eye Hospital, Brighton, United Kingdom
... and 19 more locations